Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Oct 26, 2026
TickeronGET DAILY SIGNALS
NRC Health (NRC) Q3 2026 Earnings Outlook: Tracking Revenue Recovery and TRCV Growth

NRC Health (NRC) Q3 2026 Earnings Outlook: Tracking Revenue Recovery and TRCV Growth

Key Takeaways

  • NRC Health is expected to report its third-quarter 2026 results in early November 2026, following a second quarter that marked a return to year-over-year revenue growth.
  • In Q2 2026, revenue rose roughly 4% year over year to $35.4 million, while adjusted earnings per share (EPS) of $0.31 far exceeded a consensus estimate of -$0.15.
  • Management guided toward sequential revenue growth in Q3 2026, with adjusted EBITDA margin expected to stay near the 27% level seen in the first half.
  • Total Recurring Contract Value (TRCV) — a leading indicator of future subscription revenue — grew 11% year over year to $151.9 million in Q2 2026.
  • A large Q1 landmark multi-solution win began generating revenue in Q3, while an anticipated roughly 40% effective tax rate may pressure reported net income.

Earnings Context and Why It Matters

National Research Corporation, which operates as NRC Health, delivers subscription-based healthcare experience and market intelligence software to health systems. Its quarterly earnings are closely watched because nearly 99% of revenue is recurring, making TRCV the clearest signal of future top-line direction. After a challenging 2024 and 2025 marked by elevated client attrition, the company has pivoted toward a refined sales strategy that produced an 86% jump in full-year new sales and five-plus consecutive quarters of TRCV growth. This Q3 2026 report tests whether that momentum can convert into durable, profitable revenue expansion while management absorbs investment costs and a heavier second-half tax burden. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Earnings Expectations

NRC Health does not provide formal EPS guidance each quarter, so investors lean on management commentary and trend lines. For Q3 2026, leadership has signaled sequential revenue growth, with adjusted EBITDA margin expected to remain roughly in line with the 27% posted during the first half of the year. That reflects timing pressure from the company's annual customer conference, historically held in the third quarter, which raises selling, general, and administrative expenses.

For context, Q2 2026 delivered revenue of $35.39 million (up 3.98% year over year) and adjusted EPS of $0.31, while GAAP results swung to a net loss of $3.3 million, largely due to previously announced accelerated stock vesting and related cash bonuses. Watch for TRCV, which reached $151.9 million in Q2, as well as any commentary on retention and new-sales pipeline. Management also flagged that an effective tax rate near 40% in Q3 and Q4 could compress reported net income relative to prior quarters.

Market Reaction and Investor Sentiment

Sentiment heading into Q3 2026 earnings is cautiously constructive. NRC Health shares advanced about 5% in the session following its July Q2 report, reflecting investor relief that revenue returned to growth and that adjusted results handily beat consensus. Still, lingering concerns remain around competitive disruption following the Qualtrics–Press Ganey acquisition, which closed in May and prompted two active request-for-proposal (RFP) processes to pause for reassessment. Investors will be watching whether pipeline conversion resumes and whether margin guidance for the back half of the year holds up amid elevated operating and tax costs.

Forward Outlook and Key Factors to Monitor

The most important forward indicator remains TRCV. After growing 11% year over year to $151.9 million in Q2 2026, continued sequential expansion would support the view that recognized revenue can keep climbing into 2027.

Investors should also monitor the ramp of the company's large Q1 landmark win. That multi-solution engagement went live with an initial 25 hospitals plus ambulatory sites, with full deployment targeted by year-end and revenue recognition beginning in Q3. A separate rounding-platform purchase from the same customer is expected to launch in the second half of 2027, offering a longer-dated catalyst.

On the cost side, the annual customer conference timing and a roughly 40% effective tax rate are likely to weigh on Q3 and Q4 reported results, even as adjusted EBITDA margin is expected to improve in the fourth quarter as revenue scales and expenses normalize. Finally, watch cross-sell traction: management has noted that about 70% of customers currently buy only one NRC product, a dynamic that frames a meaningful expansion opportunity if the company's AI-enabled offerings and ambient-listening rounding tools continue to gain adoption.

Exploring Tickeron’s AI Screener for Earnings Research

In my own research process, Tickeron’s AI Screener has become a useful companion when preparing for earnings seasons like this one. It lets me quickly filter stocks and ETFs by technical patterns, fundamentals, trends, and AI-driven signals to surface relevant ideas and compare names within the same space. This approach helps refine watchlists efficiently without relying solely on manual screening.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: NRC

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


NRC's RSI Oscillator peaks and leaves overbought zone

The 10-day RSI Oscillator for NRC moved out of overbought territory on November 12, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 20 instances where the indicator moved out of the overbought zone. In 17 of the 20 cases the stock moved lower in the days that followed. This puts the odds of a move down at 85%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NRC as a result. In 75 of 102 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 74%.

The Moving Average Convergence Divergence Histogram (MACD) for NRC turned negative on November 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 38 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NRC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 77%.

NRC broke above its upper Bollinger Band on November 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.

NRC moved above its 50-day moving average on October 22, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for NRC crossed bullishly above the 50-day moving average on October 27, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.

Following a +0.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where NRC advanced for three days, in 209 of 295 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.

The Aroon Indicator entered an Uptrend today. In 100 of 167 cases where NRC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 60%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 26 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. NRC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: NRC's P/B Ratio (87.343) is very high in comparison to the industry average of (4.523). NRC's P/E Ratio (107.750) is considerably higher than the industry average of (12.601). Projected Growth (PEG Ratio) (2.150) is also within normal values, averaging (1.536). Dividend Yield (0.025) settles around the average of (0.011) among similar stocks. P/S Ratio (3.460) is also within normal values, averaging (6.105).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NRC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teladoc Health (NYSE:TDOC).

Industry description

This industry comprises companies that provide services, such as equipment sterilization, research, physician management systems and consulting, that support the healthcare/medical industry. Examples of such companies include Laboratory Corporation of America Holdings, which operates one of the largest clinical laboratory networks in the world; Quest Diagnostics Inc., which is a clinical laboratory; and Syneos Health, which is a major clinical research organization.

Market Cap

The average market capitalization across the Services to the Health Industry Industry is 3.31B. The market cap for tickers in the group ranges from 708 to 49.18B. VEEV holds the highest valuation in this group at 49.18B. The lowest valued company is OTRKQ at 708.

High and low price notable news

The average weekly price growth across all stocks in the Services to the Health Industry Industry was -13%. For the same Industry, the average monthly price growth was -13%, and the average quarterly price growth was 2%. DRIO experienced the highest price growth at 5%, while LFMD experienced the biggest fall at -34%.

Volume

The average weekly volume growth across all stocks in the Services to the Health Industry Industry was 27%. For the same stocks of the Industry, the average monthly volume growth was 34% and the average quarterly volume growth was -7%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 53
Price Growth Rating: 58
SMR Rating: 86
Profit Risk Rating: 97
Seasonality Score: -5 (-100 ... +100)
Trend Prediction Engine 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of market research services for the healthcare industry

Industry ServicestotheHealthIndustry

Industry
Servicestothe Health Industry
Address
5601 South 59th Street
Phone
+1 800 388-4264
Employees
357
Web
https://www.nrchealth.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.